Liraglutide (0.3 mg/kg twice daily) was administered for 8 weeks in streptozotocin-induced diabetes in Sprague Dawley rats, which prevented the progression of diabetic nephropathy by modulating the crosstalk between transient receptor potential canonical 6 (TRPC6) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidases [26]. Here, TRPC6 is linked to diabetic kidney disease.